Skip to main content

Pacira BioSciences, Inc.

corporate_fare Company Profile

Pacira BioSciences, Inc.

PCRX·NASDAQ·Life Sciences·CIK 0001396814

Pacira BioSciences, Inc. is a Delaware corporation that serves as the holding company for its California operating subsidiary, Pacira Pharmaceuticals, Inc. The company's mission is to deliver innovative, non-opioid pain therapies. Pacira BioSciences, Inc. was incorporated in Delaware in December 2006 as Blue Acquisition Corp., changing its name to Pacira, Inc. in June 2007, then to Pacira Pharmaceuticals, Inc. in October 2010, and finally to Pacira BioSciences, Inc. in April 2019. Its principal executive offices and corporate headquarters are located in Brisbane, California. The company has expanded through several acquisitions. In March 2007, it acquired Pacira Pharmaceuticals, Inc. from SkyePharma Holdings, Inc. (now Vectura Group Limited, a subsidiary of Molex Asia Holdings, Ltd.). In April 2019, Pacira BioSciences, Inc. acquired MyoScience, Inc., a privately held medical technology company. This was followed by the acquisition of Flexion Therapeutics, Inc., a publicly traded biopharmaceutical company, in November 2021. Most recently, in February 2025, the company acquired GQ Bio Therapeutics GmbH, a privately-held biopharmaceutical company. Key trademarks and service marks owned by Pacira include Pacira®, EXPAREL®, ZILRETTA®, iovera®°, and the Pacira logo.

Pacira BioSciences, Inc. (NASDAQ:PCRX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 52 items for PCRX at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Glass Lewis Backs Pacira Management in Proxy Fight, Citing 'Actionable Plan'
  • Pacira Seeks Board Support, Touts EXPAREL's Opioid & Cost Reduction Data
  • Pacira BioSciences Defends Strategy & Performance Amidst Proxy Battle, Reports Strong Q1 2026 Growth
  • Pacira Rejects Activist Claims, Highlights Performance Ahead of Shareholder Vote
  • Pacira's EXPAREL Linked to Reduced Opioid Use, Lower Costs in Shoulder Surgery Study

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$726.41M
Net Income
$7.03M
Diluted EPS
$0.16
Op. Cash Flow
$151.99M
Free Cash Flow
$136.66M
Gross Profit
$576.66M
Operating Income
$19.19M
Cash & Equivalents
$158.54M
Total Debt
$372.19M
Debt / Equity
0.54×
Net Margin
1.0%
Shares Outstanding
41.12M sh
Source: 10-K · filed 2026-02-26 · accession 0001628280-26-012297
$36.49
52-week range · as of 2026-11-12 $18.8 – $36.66
Market cap
$1.46B
Volume
1.8M (0.8× avg)
3-mo avg 2.2M
Last traded · 2026-11-18

show_chartPrice Chart

Loading chart...

feed PCRX - Filings & News (Page 2)

PCRX
May 28, 2026, 4:25 PM EDT
Source: Dow Jones Newswires
Importance Score:
9
Price at Filing: $23.68
Real-time Price: $36.49 info
Change: +$12.81 (+54%) info
Market Cap: $1.463B info
PCRX
May 28, 2026, 3:14 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $24.04
Real-time Price: $36.49 info
Change: +$12.45 (+52%) info
Market Cap: $1.463B info
PCRX
May 27, 2026, 4:59 PM EDT
Filing Type: DEFA14A
Importance Score:
8
Price at Filing: $24.04
Real-time Price: $36.49 info
Change: +$12.45 (+52%) info
Market Cap: $1.463B info
PCRX
May 27, 2026, 4:20 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $24.04
Real-time Price: $36.49 info
Change: +$12.45 (+52%) info
Market Cap: $1.463B info
PCRX
May 27, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $24.69
Real-time Price: $36.49 info
Change: +$11.80 (+48%) info
Market Cap: $1.463B info
PCRX
May 26, 2026, 4:26 PM EDT
Filing Type: DEFA14A
Importance Score:
7
Price at Filing: $24.36
Real-time Price: $36.49 info
Change: +$12.13 (+50%) info
Market Cap: $1.463B info
PCRX
May 21, 2026, 5:08 PM EDT
Filing Type: DFAN14A
Importance Score:
9
Price at Filing: $23.48
Real-time Price: $36.49 info
Change: +$13.01 (+55%) info
Market Cap: $1.463B info
PCRX
May 21, 2026, 3:14 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $23.00
Real-time Price: $36.49 info
Change: +$13.49 (+59%) info
Market Cap: $1.463B info
PCRX
May 20, 2026, 5:24 PM EDT
Filing Type: DEFA14A
Importance Score:
9
Price at Filing: $23.00
Real-time Price: $36.49 info
Change: +$13.49 (+59%) info
Market Cap: $1.463B info
PCRX
May 20, 2026, 3:36 PM EDT
Filing Type: DFAN14A
Importance Score:
9
Price at Filing: $23.08
Real-time Price: $36.49 info
Change: +$13.42 (+58%) info
Market Cap: $1.463B info
PCRX
May 19, 2026, 7:00 PM EDT
Filing Type: DEFA14A
Importance Score:
9
Price at Filing: $22.30
Real-time Price: $36.49 info
Change: +$14.19 (+64%) info
Market Cap: $1.463B info
PCRX
May 13, 2026, 1:53 PM EDT
Filing Type: DFAN14A
Importance Score:
9
Price at Filing: $23.01
Real-time Price: $36.49 info
Change: +$13.49 (+59%) info
Market Cap: $1.463B info
PCRX
May 12, 2026, 5:23 PM EDT
Filing Type: DEFC14A
Importance Score:
9
Price at Filing: $22.84
Real-time Price: $36.49 info
Change: +$13.65 (+60%) info
Market Cap: $1.463B info
PCRX
May 12, 2026, 4:08 PM EDT
Filing Type: DFAN14A
Importance Score:
9
Price at Filing: $22.84
Real-time Price: $36.49 info
Change: +$13.65 (+60%) info
Market Cap: $1.463B info
PCRX
May 12, 2026, 4:02 PM EDT
Filing Type: DEFA14A
Importance Score:
9
Price at Filing: $22.84
Real-time Price: $36.49 info
Change: +$13.65 (+60%) info
Market Cap: $1.463B info
PCRX
May 05, 2026, 4:22 PM EDT
Filing Type: DEFA14A
Importance Score:
9
Price at Filing: $24.79
Real-time Price: $36.49 info
Change: +$11.70 (+47%) info
Market Cap: $1.463B info
PCRX
Apr 29, 2026, 6:50 PM EDT
Filing Type: PRRN14A
Importance Score:
9
Price at Filing: $24.91
Real-time Price: $36.49 info
Change: +$11.58 (+46%) info
Market Cap: $1.463B info
PCRX
Apr 28, 2026, 4:20 PM EDT
Filing Type: DEFA14A
Importance Score:
9
Price at Filing: $25.41
Real-time Price: $36.49 info
Change: +$11.08 (+44%) info
Market Cap: $1.463B info
PCRX
Apr 28, 2026, 4:15 PM EDT
Filing Type: DEFC14A
Importance Score:
9
Price at Filing: $25.41
Real-time Price: $36.49 info
Change: +$11.08 (+44%) info
Market Cap: $1.463B info
PCRX
Apr 27, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $24.69
Real-time Price: $36.49 info
Change: +$11.80 (+48%) info
Market Cap: $1.463B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets